000919 Stock Overview
Manufactures and sells pharmaceutical products and medical devices in China.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Jinling Pharmaceutical Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥6.42 |
| 52 Week High | CN¥10.13 |
| 52 Week Low | CN¥5.38 |
| Beta | 0.47 |
| 11 Month Change | -6.96% |
| 3 Month Change | -2.73% |
| 1 Year Change | -22.37% |
| 33 Year Change | 0.16% |
| 5 Year Change | -10.21% |
| Change since IPO | -53.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| 000919 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -8.7% | -1.9% | -1.2% |
| 1Y | -22.4% | -5.0% | 3.1% |
Return vs Industry: 000919 underperformed the CN Pharmaceuticals industry which returned -5% over the past year.
Return vs Market: 000919 underperformed the CN Market which returned 3.1% over the past year.
Price Volatility
| 000919 volatility | |
|---|---|
| 000919 Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in CN Market | 12.0% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 000919 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 000919's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 4,871 | n/a | jlyy1999.com |
Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products and medical devices in China. The company provides Mailuoning injection/oral solutions for the treatment of thromboangiitis obliterans, arteriosclerosis obliterans, cerebral thrombosis and sequelae, polyarteritis, acute arterial embolism of extremities, diabetic gangrene, intravenous thrombus, thrombophlebitis, etc.; ferrous succinate tablets for the prevention and treatment of iron deficiency anemia; lentinan injection for the treatment of malignant tumors; and absorbable gelatin sponges for the treatment of wound hemostasis. It also offers medical and health care services.
Jinling Pharmaceutical Company Limited Fundamentals Summary
| 000919 fundamental statistics | |
|---|---|
| Market cap | CN¥4.04b |
| Earnings (TTM) | CN¥73.41m |
| Revenue (TTM) | CN¥2.90b |
55.0x
P/E Ratio1.4x
P/S RatioIs 000919 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 000919 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.90b |
| Cost of Revenue | CN¥2.32b |
| Gross Profit | CN¥586.36m |
| Other Expenses | CN¥512.95m |
| Earnings | CN¥73.41m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 20.21% |
| Net Profit Margin | 2.53% |
| Debt/Equity Ratio | 0% |
How did 000919 perform over the long term?
See historical performance and comparison